Lotus warns funding and production risks threaten Kayelekera’s path to cash flow

Kayelekera restart meets production, misses steady-state target

Lotus Resources Limited (ASX:LOT) has crossed the symbolic line from uranium developer to producer, but its first year of operations has exposed how far that status remains from reliable commercial cash generation. Kayelekera produced 332.1 thousand pounds of U3O8 in FY2026, the first uranium concentrate from the Malawi mine since 2014, yet the operation had not achieved steady-state production by year-end.

Output improved materially during the ramp-up, rising from 14.2 thousand pounds in January 2026 to 73.6 thousand pounds in May. That progress was interrupted in June, when sulphuric acid stockouts and delays commissioning the mine’s own acid plant led to a temporary suspension of processing. The company also identified deficiencies in sampling, metallurgical accounting and production reconciliation, prompting independent reviews and revisions to previously reported operating information.

Losses and cash burn put funding at the centre

The financial statements show the cost of the delayed ramp-up. Lotus reported a $100.1 million loss after tax for the year, compared with a $15.6 million loss in FY2025, while operating cash outflow climbed to $114.9 million. Cash and cash equivalents stood at $30.2 million at 30 June, down from $54.1 million a year earlier, despite $144.5 million raised through two equity raisings during the year.

RSM Australia Partners issued an unmodified audit opinion, but highlighted a material uncertainty related to going concern. The auditor said Lotus remains dependent on Kayelekera achieving forecast production and cash generation, maintaining reliable processing, controlling expenditure and retaining access to funding. The directors’ base case assumes sufficient liquidity, but the report also recognises downside risks including further production interruptions, lower uranium sales, higher costs and delays to export receipts.

Funding package adds liquidity but increases shareholder exposure

Lotus subsequently completed a fully underwritten A$60.1 million entitlement offer and issued A$35 million of senior unsecured convertible notes to CVI Investments, alongside detachable warrants. The post-year-end package is intended to fund operational optimisation and the transition to commercial sales, while a binding commitment letter with Mercuria covers a proposed US$30 million inventory-backed prepayment facility and uranium marketing arrangement. The Mercuria facility remains subject to relevant conditions and definitive documentation.

The funding carries a clear trade-off. It provides additional runway while the company tries to restart and stabilise Kayelekera, but the entitlement offer materially expanded the share count and the convertible notes are exercisable at a variable price with a floor of $0.11. Existing shareholders are therefore being asked to absorb further dilution while the mine’s operating model is still being tested.

Exports and offtake obligations remain unresolved

Product acceptance by Orano Chimie-Enrichissement in April was an important commercial step: Orano had accepted 159.5 thousand pounds of the 332.1 thousand pounds produced by 30 June. Lotus is developing an export route through Walvis Bay after disruptions affected the original Dar es Salaam pathway, but first shipments remained dependent on permits, product preparation and logistics arrangements at the reporting date.

The delay matters because Lotus entered FY2026 with binding sales agreements covering about 3.8 million pounds of U3O8 between 2026 and 2029. The accounts recognise a US$3.24 million, or A$4.62 million, payable linked to 300,000 pounds of undelivered product. Customer discussions over delivery schedules and settlement arrangements were still continuing, leaving the timing of revenue and working-capital recovery as a central test for the restart.

Letlhakane offers longer-term potential, not immediate relief

Lotus also reported encouraging early technical work at its Letlhakane project in Botswana. ANSTO testwork indicated the potential to reduce acid consumption by about 70%, with an estimated 6% to 8% reduction in uranium recovery, while simplifying the proposed processing route. Resource conversion drilling at Serule West also completed 4,553 metres, with all holes intersecting uranium mineralisation, although the programme was incomplete at year-end and its results were not included in the current resource estimate.

That work supports Letlhakane’s role as Lotus’ longer-term growth asset, but it does not solve the immediate Kayelekera funding and execution problem. The next evidence will need to come from sustained production, successful acid plant remediation, completed export approvals and actual uranium sales receipts. Until those arrive, the company’s transition to producer status remains more of a capital-intensive work in progress than a finished transformation.